Jazz pharmaceuticals plcJAZZ.US Overview
JAZZ Overall Performance
JAZZ AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
JAZZ Current Performance
-2.81%
Jazz pharmaceuticals plc
-0.58%
Avg of Sector
0.83%
S&P500
JAZZ Key Information
JAZZ Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
JAZZ Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
JAZZ Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Price of JAZZ
JAZZ FAQ
When is JAZZ's latest earnings report released?
The most recent financial report for Jazz pharmaceuticals plc (JAZZ) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JAZZ's short-term business performance and financial health. For the latest updates on JAZZ's earnings releases, visit this page regularly.
What is the operating profit of JAZZ?
According to the latest financial report, Jazz pharmaceuticals plc (JAZZ) reported an Operating Profit of -686.39M with an Operating Margin of -65.64% this period, representing a decline of 444.15% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is JAZZ's revenue growth?
In the latest financial report, Jazz pharmaceuticals plc (JAZZ) announced revenue of 1.05B, with a Year-Over-Year growth rate of 2.14%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does JAZZ have?
As of the end of the reporting period, Jazz pharmaceuticals plc (JAZZ) had total debt of 5.42B, with a debt ratio of 0.5. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does JAZZ have?
At the end of the period, Jazz pharmaceuticals plc (JAZZ) held Total Cash and Cash Equivalents of 1.19B, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does JAZZ go with three margins increasing?
In the latest report, Jazz pharmaceuticals plc (JAZZ) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.9%%, operating margin of -65.64%%, and net margin of -68.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess JAZZ's profit trajectory and future growth potential.
Is JAZZ's EPS continuing to grow?
According to the past four quarterly reports, Jazz pharmaceuticals plc (JAZZ)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -11.74. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JAZZ?
Jazz pharmaceuticals plc (JAZZ)'s Free Cash Flow (FCF) for the period is 75.89M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 76.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of JAZZ?
The latest valuation data shows Jazz pharmaceuticals plc (JAZZ) has a Price-To-Earnings (PE) ratio of -15.87 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.